Crossmark

An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK

Published Online: 2020-02-07

Published Print: 2020-03

Authors

Viriato, Daniel

Bennett, Natalie

Sidhu, Raisa

Hancock, Elizabeth

Lomax, Hannah

Trueman, David

MacLaren, Robert E.
Funding

Funding for this research was provided by:

Novartis Pharma AG
License Information

Text and Data Mining valid from 2020-02-07

Version of Record valid from 2020-02-07
More Information

Article History

Received: 12 December 2019

First Online: 7 February 2020

Document is current